AptarGroup Accused of Monopolizing Market for Nasal Spray System

AptarGroup Inc. was sued in federal court by a customer claiming the company monopolizes the market for single-dose intranasal spray systems for emergency use.

Plaintiff ARS Pharmaceuticals Operations Inc., a direct purchaser of components from Aptar for its own nasal spray product, claims it was forced to pay higher prices “than would prevail in a market unrestrained by Aptar’s exclusionary conduct,” it said in a Monday complaint filed in the US District Court for the Southern District of California.

ARS is a biopharmaceutical company that sources components of its “neffy” intranasal treatment spray for allergic reactions from Aptar. Aptar is ...